CAMBRIDGE, Md., Nov. 17, 2020 /PRNewswire/ — OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS) and other deadly cancers in children and adults, today announced the acquisition of all indications for OST-HER2 (Listeria monocytogenes), including Canine. The technology that was developed and extensively tested at University of Pennsylvania, has been provisionally approved by the USDA for Osteosarcoma in canines. Phase I and Phase III trials conducted in canines have had very positive results.
{iframe}https://www.prnewswire.com/news-releases/os-therapies-acquires-all-indications-for-ost-her2-listeria-monocytogenes-in-solid-tumors-including-canines-301174449.html{/iframe}